PDCD1 and hepatocellular carcinoma: A phase I dose escalation study to investigate the safety, immunoregulatory activity, pharmacokinetics, and preliminary antitumor activity of anti-programmed-death-1 (PD-1) antibody (BMS-936558) in advanced hepatocellular carcinoma in subjects with or without chronic viral hepatitis.